...
首页> 外文期刊>Journal of vascular surgery >Blood coagulation and fibrinolytic response after endovascular stent grafting of thoracic aorta.
【24h】

Blood coagulation and fibrinolytic response after endovascular stent grafting of thoracic aorta.

机译:胸主动脉血管内支架置入术后的凝血和纤溶反应。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Thrombosis is common in aneurysms immediately after stent-grafting, because of exclusion from systemic blood flow. We studied changes in blood coagulation and the fibrinolytic system in patients with thoracic aortic aneurysm or dissection after stent-grafting to examine risk for consumption coagulopathy. METHODS: Thirty-one thoracic aortic aneurysms were treated with stent-grafting (aneurysm group), and 29 aortic dissections were treated with entry closure with stent-grafting (dissection group). The stent-graft was constructed from a self-expanding Z stent and thin-walled woven polyester fabric. Platelet count, fibrinogen, antithrombin III (AT III), and thrombin-AT III complex were assayed as markers of coagulation. Plasminogen, alpha(2)-plasmin inhibitor, alpha(2)-plasmin inhibitor-plasmin complex, fibrin degradation products fragment E (FDP-E), and fibrin degradation products d-dimer were monitored as markers of fibrinolysis. Blood samples were collected before surgery and on postoperativedays 1, 3, 7, and 14. RESULTS: In both groups platelet count significantly decreased on postoperative days 1 and 3, and increased on postoperative day 14. AT III significantly decreased on postoperative day 1, but recovered after postoperative day 7. FDP-E significantly increased on postoperative day 1 in both groups. There was significant correlation of aneurysm diameter with alpha(2)-plasmin inhibitor-plasmin complex, fibrin degradation products, and d-dimer in the dissection group on postoperative day 1. CONCLUSIONS: Activation of coagulation and fibrinolysis was observed after stent-grafting to treat thoracic aortic aneurysm and aortic dissection. However, no patients exhibited consumption coagulopathy postoperatively. Therefore we believe there is little risk for consumption coagulopathy after stent-grafting.
机译:目的:由于系统血流的排斥,在支架移植后即刻在动脉瘤中血栓形成很常见。我们研究了支架植入后胸主动脉瘤或夹层患者血液凝固和纤溶系统的变化,以检查消耗性凝血病的风险。方法:对31例胸主动脉瘤行覆膜支架治疗(动脉瘤组),对29例主动脉夹层进行支架置入术治疗(夹层动脉瘤)。支架移植物由自膨胀Z支架和薄壁机织聚酯纤维制成。测定血小板计数,纤维蛋白原,抗凝血酶III(AT III)和凝血酶-AT III复合物作为凝血的标志物。监测纤溶酶原,α(2)-纤溶酶抑制剂,α(2)-纤溶酶抑制剂-纤溶酶复合物,纤维蛋白降解产物片段E(FDP-E)和纤维蛋白降解产物d-二聚体作为纤维蛋白溶解的标记物。手术前和术后第1、3、7和14天采集血样。结果:两组的血小板计数在术后第1天和第3天显着减少,在术后第14天增加。ATIII在术后第1天显着减少。但术后7天后恢复。两组FDP-E均在术后1天显着增加。术后第1天的解剖组中,动脉瘤直径与α(2)-纤溶酶抑制剂-纤溶酶复合物,纤维蛋白降解产物和d-二聚体之间存在显着相关性。结论:支架植入后,观察到凝血和纤维蛋白溶解的激活。治疗胸主动脉瘤和主动脉夹层。但是,没有患者术后出现消耗性凝血病。因此,我们认为支架移植后发生消耗性凝血病的风险很小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号